INTRODUCTION {#s1}
============

Nasopharyngeal carcinoma (NPC) has a distinct epidemiology and geographic distribution, with the highest incidence of 20-50 cases per 100,000 males in Southern China \[[@R1]\]. Radiotherapy (RT) is the primary treatment modality for non-disseminated NPC due to its anatomical location and radiosensitivity \[[@R2]\]; however, the results with radiotherapy alone for locoregionally advanced NPC patients are usually unsatisfactory with 5-year overall survival (OS) rates of 67%-77% in stage III-IVB \[[@R3]\]. Various chemoradiotherapy (CRT) strategies have been explored, including concomitant chemoradiotherapy (CCRT), induction chemotherapy (IC) and adjuvant chemotherapy (AC)\[[@R4]\].

At present, standard clinical practice is to stage NPC according to the tumor-node-metastasis (TNM) staging system, which is based on the anatomic extent of the tumor and excluded patient-based prognostic factors. Comorbidity which is defined as the presence of medical ailments not caused by the primary tumor may add difficulty to treatment decisions for the use of chemotherapy \[[@R5]\]. In addition, as CRT strategies are widely used, it may exacerbate comorbidity, which may ultimately compromise survival or quality of life \[[@R6]\]. Therefore, The risks, decision making and potential benefit of CRT are necessary to assess for NPC patients with comorbidity before treatment.

Previous studies showed that patients with comorbidities received less, similar or more frequent uses of chemotherapy in different solid tumor \[[@R6]\]. However, little is known about outcome of CRT in patients with comorbidity, as comorbidities are generally not considered in the design of cancer data sets or assessed in observational research on the selection of CRT \[[@R7]\]. For NPC patients, no studies have investigated the impact of comorbidity on the selection of CRT and clinical outcome in NPC. We conducted this retrospective study to assess the impact of comorbidity on treatment selection and its ultimate effect on survival, in order to help optimize cancer care for patients with NPC undergoing CRT.

RESULTS {#s2}
=======

The median follow-up was 75.3 months (range, 2.7-126.5 months). A total of 125/1316 (9.5%) patients developed local failure, 52/1316 (4.9%) developed regional failure, 19/1316 (1.4%) developed both local and regional failure, 233/1316 (17.7%) developed distant metastases, and 291/1316 (22.1%) patients died. The 5-year DFS, OS, DMFS and LRRFS rates were 71.7%, 79.5%, 82.5% and 87.9%, respectively.

Differences of the patients with or without comorbidity {#s2_1}
-------------------------------------------------------

The overall distribution of stage I, II, III and IVA-B diseases was 8.7%, 25.4%, 36.9% and 29.0%, respectively. There was no association between disease stage and comorbidity, as indicated by ACE-27; however, the stage III-IV NPC patients with comorbidity (ACE-27 \> 0) significantly received decreased chemotherapy compared with patients without comorbidity (67.6%vs.74.0%; P = 0.037). Furthermore, the significant associations were also observed between comorbidity and gender, age and type of radiotherapy (P \< 0.05; Table [1](#T1){ref-type="table"}).

###### Characteristics of the 1316 patients with nasopharyngeal carcinoma

  ----------------------------------------------------------------------------------
  Patient characteristics            Without comorbidity\   With\          P-value
                                     (ACE-27=0)             Comorbidity\   
                                                            (ACE-27\>0)    
  ---------------------------------- ---------------------- -------------- ---------
  **No**                             761                    555            

  **Age**                                                                  \<0.001

  \< 45 years                        444 (58.3)             239(43.1)      

  ≥ 45 years                         317(41.7)              316(56.9)      

  **Gender**                                                               \<0.001

  Male                               537 (70.6)             449 (80.6)     

  Female                             224 (29.4)             106 (19.1)     

  **Histology**                                                            0.660

  WHO type I                         4 (0.5)                2 (0.4)        

  WHO type II/III                    757(99.5)              553 (99.6)     

  **T classification\***                                                   0.744

  T1                                 171 (22.5)             119 (21.4)     

  T2                                 175 (23.0)             128 (23.1)     

  T3                                 254 (33.4)             177 (31.9)     

  T4                                 161 (21.2)             131 (23.6)     

  **N classification\***                                                   0.203

  N0                                 211 (27.7)             177 (31.9)     

  N1                                 344 (45.2)             235 (42.3)     

  N2                                 147 (19.3)             92(16.6)       

  N3                                 59 (7.8)               51 (9.2)       

  **Clinical stage\***                                                     0.339

  I                                  63 (8.3)               52 (9.4)       

  II                                 201 (26.4)             133 (24.0)     

  III                                289 (38.0)             197 (35.5)     

  IVA-B                              208 (27.3)             173 (31.2)     

  **Radiotherapy**                                                         0.002

  2-DRT                              418 (54.9)             352 (63.4)     

  3-DRT or IMRT                      343 (45.1)             203 (36.6)     

  **Chemotherapy in stage III-IV**                                         0.037

  RT only                            129 (26.0)             120 (32.4)     

  RT+chemotherapy                    368 (74.0)             250 (67.6)     
  ----------------------------------------------------------------------------------

Abbreviations: WHO, World Health Organization; 2-DRT, two-dimensional radiotherapy; 3-DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; RT

\* According to the 7th AJCC/UICC staging system.

Prevalence, types and prognostic value of comorbidity {#s2_2}
-----------------------------------------------------

Of the 1316 patients, 555 (42.2%) had one or more comorbidity; 442 (33.6%) patients had ACE-27 scores of 1, 106 (8.1%) had scores of 2, and 7 (0.5%) had scores of 3. Gastrointestinal disease (24.9%), substance abuse (12.9%) and cardiovascular disease (5.4%) were most frequently observed (Table [2](#T2){ref-type="table"}).

###### Presence and severity of comorbidity in the study population of 1316 patients with NPC

  -------------------------------------------------------------------------
  Disease classification\     Grade 1:\     Grade 2: moderate   Grade 3:\
  according to ACE-27         mild                              severe
  --------------------------- ------------- ------------------- -----------
  Overall ACE27 score         442 (33.6%)   106 (8.1%)          7 (0.5%)

  Specific ACE27 categories                                     

  Cardiovascular system       64 (4.9%)     7 (0.5%)            0 (0.0%)

  Respiratory system          25 (1.9%)     4 (0.3%)            0 (0.0%)

  Gastrointestinal system     317 (24.1%)   11 (0.8%)           0 (0.0%)

  Renal system                34 (2.6%)     0 (0.0%)            0 (0.0%)

  Endocrine system            21 (1.6%)     2 (0.2%)            0 (0.0%)

  Neurological system         6 (0.5%)      0(0.0%)             0 (0.0%)

  Psychiatric                 1 (0.1%)      0 (0.0%)            0 (0.0%)

  Rheumatologic               2 (0.2%)      0 (0.0%)            0 (0.0%)

  Immunological system        0 (0.0%)      0 (0.0%)            0 (0.0%)

  Malignancy                  4 (0.3%)      5 (0.4%)            5 (0.4%)

  Substance abuse             89 (6.8%)     80 (6.1%)           0 (0.0%)

  Body weight                 1 (0.1%)      1 (0.1%)            0 (0.0%)
  -------------------------------------------------------------------------

Abbreviation: ACE-27, Adult Comorbidity Evaluation-27.

In univariate analysis, the 5-year OS rates of patients with ACE-27 grades of 0, 1 and ≥ 2 were 85.2%, 74.3% and 63.2% (P \< 0.001; Figure [1A](#F1){ref-type="fig"}). The 5-year DFS rates of patients with ACE-27 grades of 0, 1 and ≥ 2 were 77.6%, 67.4% and 50.2% (P \< 0.001; Figure [1B](#F1){ref-type="fig"}). In multivariate analysis, ACE-27 had significant independent prognostic value for OS (hazard ratio \[HR\] = 1.577; P \< 0.001) and DFS (HR = 1.509; P \< 0.001; Table [3](#T3){ref-type="table"}).

![Kaplan-Meier estimates of survival for the 1316 study patients with nasopharyngeal cancer, according to ACE27 grade\
**A.** Overall survival, **B.** disease-free survival.](oncotarget-08-10594-g001){#F1}

###### Multivariate analysis of the impact of all variables on survival

  Endpoint                    Variable             HR      HR (95% CI)   P-value‡
  --------------------------- -------------------- ------- ------------- ----------
  **Overall survival**        ACE-27               1.577   1.345-1.850   \<0.001
                              T classification\*   1.548   1.374-1.744   \<0.001
                              N classification\*   1.695   1.499-1.916   \<0.001
                              Age                  1.376   1.088-1.740   0.008
  **Disease-free survival**   ACE-27               1.509   1.314-1.734   \<0.001
                              T classification\*   1.452   1.314-1.605   \<0.001
                              N classification\*   1.527   1.373-1.698   \<0.001

Abbreviation: ACE-27, Adult Comorbidity Evaluation-27; CI, confidence interval; HR, hazard ratio.

\*According to the 7th AJCC/UICC staging system.

‡ Multivariate P values were calculated using an adjusted Cox proportional-hazards model. The following parameters were included in the Cox proportion hazard model by backward elimination: age, gender, World Health Organization (WHO) histological grade, T classification, N classification, radiotherapy (conformal vs. 3D and intensity modulated radiation therapy), use of chemotherapy (with vs. without) and ACE-27.

Factors associated with initiation of CRT in advanced stage disease {#s2_3}
-------------------------------------------------------------------

For stage III-IV NPC patients, T classification, N classification, age, sex and hemoglobin before treatment and comorbidity (with vs. without) were significantly associated with the initiation of CRT in univariate analysis (P \< 0.05; Table [4](#T4){ref-type="table"}). And the T classification, N classification, age, sex and hemoglobin before treatment were significantly associated with the initiation of CRT in multivariable logistic regression (P \< 0.05; Table [4](#T4){ref-type="table"}). Furthermore, patients with a higher renal system burden and substance abuse were less likely to receive CRT (P = 0.068; P = 0.017; Table [4](#T4){ref-type="table"}).

###### Logistic regression analyses of factors associated with the uptake of chemotherapy by patients with stage III-IV nasopharyngeal carcinoma

  Characteristic                      No.   HR      95% CI for HR   Univariate *P*-value†   Multivariate *P*-value‡
  ----------------------------------- ----- ------- --------------- ----------------------- -------------------------
  **Age (y)**                         867   0.977   0.961-0.993     \<0.001                 0.003
  **Sex**                                                           0.008                   \<0.001
  Male                                649   1       Reference                               
  Female                              218   0.317   0.196-0.512                             
  **Histological type**                                             0.362                   NS
  WHO type I                          4             Reference                               
  WHO type II-III                     863   1.392   0.169-11.443                            
  Hematology                                                                                
  Hemoglobin                          867   0.968   0.955-0.981     \<0.001                 \<0.001
  Platelet                            867   1.001   0.995-1.007     0.907                   NS
  White blood cell                    867   0.860   0.590-1.254     0.110                   NS
  Neutrophil                          867   1.077   0.671-1.729     0.076                   NS
  **Comorbidity present (Overall)**                                 0.037                   0.089
  Cardiovascular system               867   0.999   0.495-2.017     0.300                   NS
  Respiratory system                  867   0.756   0.282-2.024     0.264                   NS
  Gastrointestinal system             867   0.890   0.625-1.266     0.212                   NS
  Renal system                        867   0.372   0.128-1.077     0.077                   0.068
  Endocrine system                    867   0.784   0.246-2.498     0.159                   NS
  Neurological system                 867   0.899   0.112-7.220     0.580                   NS
  Malignancy                          867   1.165   0.280-4.849     0.751                   NS
  Substance abuse                     867   0.596   0.434-0.820     0.020                   0.001
  Staging                                                                                   
  **T classification§**                                                                     
  T1                                  62    1.00    Reference                               
  T2                                  82    0.218   0.085-0.554     0.507                   0.001
  T3                                  431   0.219   0.095-0.502     0.109                   \<0.001
  T4                                  292   0.462   0.297-0.721     0.001                   0.001
  **N classification§**                                                                     
  N0                                  184   1.00    Reference                               
  N1                                  334   0.123   0.049-0.310     \<0.001                 \<0.001
  N2                                  239   0.206   0.085-0.499     0.049                   \<0.001
  N3                                  110   0.363   0.163-0.808     0.038                   0.013

Abbreviations: ACE-27, Adult Comorbidity Evaluation-27; CI, confidence interval; HR, hazard ratio; NS, not statistically significant; RT, radiotherapy; WHO, World Health Organization.

† Univariate *P* values were calculated using the binary logistic regession model.

‡ Multivariate *P* values were calculated using the binary logistic regession model.

§ According to the 7th AJCC/UICC staging system.

Effect of comorbidity on CRT treatment outcomes {#s2_4}
-----------------------------------------------

For stage III-IV patients with a comorbidity (ACE \> 0), the 5-year OS rate in the CCRT group was 74.5% vs. 56.9% for RT only (P = 0.008), 65.0% for CCRT + AC/IC (P = 0.318) and 54.9% for IC/AC (P = 0.024; Figure [2A](#F2){ref-type="fig"}). The 5-year DFS rates was 64.0% in the CCRT group vs. 49.4% for RT only (P = 0.015), 57.9% for CCRT + AC/IC (P = 0.505) and 45.9% for IC/AC (P = 0.014; Figure [2B](#F2){ref-type="fig"}).

![Kaplan-Meier overall survival curves for patients with Stage III-IV nasopharyngeal cancer according to the chemotherapy strategy\
A. Overall survival for patients with comorbidity (ACE scores \> 0); B. disease-free survival for patients with comorbidity (ACE scores \> 0). Group 1: radiotherapy (RT) only; Group 2: concomitant chemoradiotherapy (CCRT); Group 3: concomitant chemoradiotherapy plus induction chemotherapy/adjuvant chemotherapy (CCRT + IC/AC): Group 4: induction chemotherapy or adjuvant chemotherapy (IC/AC).](oncotarget-08-10594-g002){#F2}

DISCUSSION {#s3}
==========

Patients with comorbidities present considerable challenges to cancer management because they are often excluded from clinical trials. To our knowledge, this is a single-institutional study with the largest sample size to report the impact of comorbidity on the uptake of chemotherapy in NPC patients.

The prevalence of comorbidity for NPC in south China {#s3_1}
----------------------------------------------------

Comorbidities occur in 33%-65% of patients with head and neck cancer, with cardiovascular and pulmonary diseases most common \[[@R7]--[@R13]\]. In our research, 42.2% of patients with NPC had comorbidity; however, the most common comorbidities were gastrointestinal disease, which, according to the ACE-27, includes liver disease. This was not surprising as southern China has one of the highest incidences of chronic hepatitis B virus (HBV) infection, with hepatitis B surface antigen (HBsAg) positivity rates of 10-12% in the general population \[[@R14]\]. Therefore, chronic HBV infection may be an important gastrointestinal comorbidity in patients with NPC in southern China. An increased frequency and severity of comorbidity were noted with increasing age and in male patients. Piccirillo et al. also reported that increased age was associated with an increasing number and severity of comorbidities \[[@R15]\] with similar results obtained in other studies \[[@R13], [@R16], [@R17]\]. In this study, the second most frequent comorbidity was substance abuse, mainly in male patients.

Factors associated with the initiation of chemotherapy in advanced stage NPC {#s3_2}
----------------------------------------------------------------------------

Age, T classification, N classification, pretreatment hemoglobin were independent predictive factors for initiation of CRT; in agreement with previous studies demonstrating elderly patients tend to receive less intensive treatment \[[@R18]\]. However, The reduction in the use of CRT was only in patients with renal disease. Chemotherapy strategies for NPC include cisplatin, the use of which is limited by its severe acute and chronic nephro-, oto- and neuro-toxicity\[[@R19]\]. In everyday practice, the initiation of CRT is not primarily determined by comorbidity conditions, but renal disease.

Implications of CRT in patients with comorbidity {#s3_3}
------------------------------------------------

Little is known about the toxicity and outcomes of CRT regimes in patients with s comorbidity, as these patients are often excluded from clinical trials. Our results indicate CCRT improved OS compared to RT only for patients with mild, moderate and severe comorbidity. Nevertheless, adding IC or AC to CCRT had no significant OS benefit. CCRT also improved OS compared to RT alone in patients with comorbidity (ACE \> 0). Therefore, if patients with advanced NPC and comorbidity desire curative treatment, we consider CCRT to be the most appropriate approach; further studies are required to identify more intensive systemic approaches and novel agents, such as molecular-targeted agents, to improve the treatment outcomes for these patients. Moreover, patients with comorbidity should receive complete supportive care during treatment to ensure optimal outcome. ACE-27 requires no special technological expertise and can be applied by any healthcare professional. Comorbidity assessment could easily be included in research into prognostic factors and could represent a major confounder in clinical trials.

Since this was a retrospective sample, we had no control over the nature and quality of the medical records. Nevertheless, the records were detailed and provided accurate information on the patients' clinical characteristics. More importantly, these results clearly demonstrate that comorbidity must be routinely considered with other significant prognostic factors in both clinical work and research. This study also justifies the need for prospective collection of comorbidity data in routine clinical practice.

CONCLUSIONS {#s4}
===========

Comorbidity information should be incorporated into treatment strategy decision-making processes, to aid patient consultation and improve clinician decision-making. Concomitant chemoradiotherapy is feasible and effective in patients with comorbidity in locoregionally advanced stages.

MATERIALS AND METHODS {#s5}
=====================

Patient selection {#s5_1}
-----------------

Between February 2003 and January 2007, 1403 newly-diagnosed patients with non-metastatic, histologically-proven NPC at Sun Yat-sen University Cancer Center (Guangzhou, People's Republic of China) were retrospectively reviewed. Of these, 87 were excluded due to a lack of substantial data on comorbidity; the remaining 1316 cases were included. This retrospective analysis of the patient data was approved by the ethics committee of Sun Yat-sen University Cancer Center. Written consent was waived, while oral consent from the patients was obtained via telephone and documented by telephone recording.

All patients completed pretreatment evaluations, including complete medical history, physical examination, MRI of the nasopharynx and neck, hematology and biochemistry profiles, abdominal ultrasonography, chest radiography and whole body bone scan using single photon emission computed tomography (ECT); 139 (10.6%) patients also underwent positron emission tomography CT (PET-CT). All patients were restaged according to the 7th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) system \[[@R20]\]. All MRI records were separately reviewed by two radiologists to minimize heterogeneity, disagreements were resolved by consensus.

Comorbidity assessment {#s5_2}
----------------------

Comorbidity was evaluated by the Adult Comorbidity Evaluation-27 (ACE-27), a validated 27-item comorbidity index specifically developed for head and neck cancer \[[@R21]--[@R23]\]. The detailed information on the patients' baseline medical condition and comorbidities (collected before diagnosis of primary NPC) were reviewed by one physician for ACE-27 scores. ACE-27 defines specific conditions using three grades (grade 0 = none; 1 = minimal; 2 = moderate; 3 = severe) according to organ system decompensation. The overall comorbidity score for each patient was based on the highest-ranked single ailmen. When two or more moderate ailments occurred in different organ systems, the overall comorbidity score was graded as severe.

Treatment {#s5_3}
---------

Radiotherapy: All patients underwent definitive RT as reported previously \[[@R24]--[@R26]\]; 770/1316 (58.5%) received two-dimensional radiotherapy (2D-CRT) and 546/1,316 (41.5%) received three-dimensional conformal radiotherapy (3-DCRT) or intensity-modulated radiotherapy (IMRT).

Chemotherapy: The majority of the patients (618 of 867; 71.3%) with stage III or IV NPC (classified as T3-T4 and = or N2-N3 disease) received chemotherapy, including CCRT+/-IC/AC. Of these, 28.3% (245/867) patients received CCRT only, 30.8% (267/867) received CCRT+IC/AC, 12.2% (106/867) received RT+IC/AC. IC or AC consisted of cisplatin (80 mg/m2) with 5-fluorouracil (800 mg/m2/day over 120 h), or cisplatin (80 mg/m2) with taxanes (80 mg/m2) every 3 weeks for two or three cycles. CCRT consisted of cisplatin (80 or 100 mg/m2) on weeks 1, 4 and 7 of radiotherapy, or cisplatin (40 mg/m2) weekly.

Follow-up and statistical analyses {#s5_4}
----------------------------------

The following end points (time to the first defining event) were assessed: overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRRFS) and distant metastasis-free survival (DMFS). Follow-up was calculated from first day of therapy to the day of death or last examination. Patients were followed-up every 3 months during the first 2 years, and every 6-12 months thereafter until death.

We used univariate analyses to examine the association of various factors with CRT. Then, multivariable logistic regression was used to calculate adjusted hazard ratio HRs. Actuarial rates were estimated by the Kaplan-Meier method, survival curves compared using the log-rank test. Multivariate analysis using a Cox proportional hazards model was used to test the different factors by backward elimination. Host factors (sex, age, ACE-27), tumor factors (histology, T and N classification), and treatment factors (RT technique and chemotherapy) were included as covariates in all analyses. Stata Statistical Package (STATA 12; StataCorp LP, College Station, Texas, USA) was used for all analysis. All tests were two-sided, P \< 0.05 was considered significant.
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